Inhibitor Therapeutics Reports Q1 2025 Financial Results with Net Loss of $632,846

Inhibitor Therapeutics, Inc. reported its financial results for the first quarter of 2025, revealing a net loss of $632,846, a decrease from the net loss of $684,711 recorded in the same period of 2024. The company did not generate any revenue during the quarter, consistent with its previous fiscal period. Total expenses for the quarter were $674,551, down from $774,817 in the prior year, primarily due to reduced research and development costs, which fell to $236,058 from $260,359, and lower general and administrative expenses, which decreased to $438,493 from $514,458.

The company's balance sheet as of March 31, 2025, showed total assets of $4,505,267, a decline from $5,694,658 at the end of 2024. This decrease was largely attributed to a reduction in cash and cash equivalents, which fell to $4,321,894 from $5,606,863. Current liabilities also decreased significantly to $94,712 from $709,618, primarily due to a reduction in accrued expenses. Stockholders' equity decreased to $1,352,194 from $1,985,040, reflecting the net loss incurred during the quarter.

In terms of strategic developments, Inhibitor Therapeutics continues to focus on the development of innovative therapeutics, particularly for basal cell carcinoma and other cancers using itraconazole, a drug already approved for treating fungal infections. The company has entered into an Exclusive License Agreement with Johns Hopkins University, granting it worldwide patent rights for a new angiogenesis inhibitor related to its cancer treatment efforts. Additionally, Inhibitor is working with Avior Bio, Inc. on a novel formulation of itraconazole, with results expected in the third quarter of 2025.

Operationally, the company maintained a consistent number of shares outstanding at 172,323,545, with no new stock options or restricted shares issued during the quarter. The company’s management indicated that the current cash reserves are sufficient to support its business plan without the need for additional clinical trials. Looking ahead, Inhibitor Therapeutics plans to engage with the FDA regarding its new drug application for the BCCNS product and will assess its capital requirements for future opportunities based on the outcomes of these discussions.